Neurological

Sildenafil, trazodone tablets that have been recalled after repackaging

Subjects ” Neurobehavioral disorders

HealthDay News – Sildenafil and trazodone tablets have been recalled by drug distributor AvKARE because the company said the drugs were “accidentally packaged together” when they were being bottled by a third party.

The recall applies to 100 mg sildenafil tablets, lot 36884 with an expiry date of 03/2022, and 100 mg trazodone tablets, lot 36783, with an expiry date of 06/2022.

AvKARE said it does not know of any patients who would be harmed by the recalled products.

For more information on the recall, AvKARE consumers can call 1-855-361-3993.

More information

Subjects:

Depression Neurobehavioral Disorders

Would you like to read more?

Please log in or register first to view this content.

Login Register

to open

Next post in Neurobehavioral Disorders

Shut down

A randomized, double-blind clinical trial published in Translational Psychiatry compared the effectiveness of treating schizophrenia with cannabidiol versus amisulpride, an antipsychotic drug.  The results of the study showed that treatment with cannabidiol and amisulpride both improved symptoms significantly.  However, cannabidiol actually showed fewer side effects than amisulpride, such as motor impairment and weight gain, which can affect adherence to treatment.  While the study results are preliminary, the researchers believe their results warrant further clinical trials.  Neuropsychological and imaging studies could also investigate whether cannabidiol can potentially reverse impaired brain function in people with schizophrenia.

Related Articles